Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bilzen – page 81

1 415 clinical trials in Bilzen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bilzen at a glance
1 415
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 415 trials in Bilzen

Open in trial search

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bilzen

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and optimization strategies for patients with chronic digestive conditions.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn

This primary care investigation evaluates various deprescribing approaches, including on-demand usage and alternative treatments, to improve long-term medication management for patients on chronic PPI therapy.

02 Primary Care Innovation

Advanced research examining optimal medication reduction strategies in the primary care setting, focusing on patient-centered approaches to decrease long-term medication use.

  • Medication Management
  • Treatment Optimization
  • Patient-Centered Care

The study compares traditional dose reduction methods with innovative approaches, including alternative therapeutic options for digestive health management.

03 Therapeutic Alternatives

Investigation into alternative treatment strategies for common digestive conditions, comparing conventional medication tapering with newer therapeutic approaches.

  • Alginate Therapy
  • On-Demand Treatment
  • Medication Reduction

Research focuses on establishing evidence-based protocols for transitioning patients from long-term PPI use to more flexible treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.